Avalyn Pharma (NASDAQ:AVLN – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.03), reports.
Avalyn Pharma Trading Down 1.7%
Shares of NASDAQ:AVLN traded down $0.53 during mid-day trading on Friday, reaching $30.06. The stock had a trading volume of 114,333 shares, compared to its average volume of 339,604. The stock has a 50 day moving average of $28.77. Avalyn Pharma has a twelve month low of $22.24 and a twelve month high of $40.17. The company has a market cap of $1.33 billion and a price-to-earnings ratio of -1.32. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12.
Insider Transactions at Avalyn Pharma
In related news, insider Fmr Llc sold 175,000 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $29.07, for a total transaction of $5,087,250.00. Following the completion of the transaction, the insider owned 2,109,535 shares in the company, valued at approximately $61,324,182.45. The trade was a 7.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Institutional Investors Weigh In On Avalyn Pharma
Several hedge funds have recently bought and sold shares of AVLN. Montanova Capital LLC acquired a new position in shares of Avalyn Pharma in the 2nd quarter valued at $82,402,000. Braidwell LP acquired a new stake in Avalyn Pharma during the 2nd quarter worth $26,382,000. State Street Corp raised its stake in Avalyn Pharma by 73.7% during the 3rd quarter. State Street Corp now owns 554,004 shares of the company’s stock worth $15,784,000 after buying an additional 235,009 shares during the period. Bank of New York Mellon Corp acquired a new stake in Avalyn Pharma during the 2nd quarter worth $1,321,000. Finally, Profund Advisors LLC bought a new position in Avalyn Pharma during the third quarter worth about $668,000.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on AVLN. Wall Street Zen cut shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Raymond James Financial began coverage on shares of Avalyn Pharma in a research note on Friday, October 2nd. They set an “outperform” rating and a $60.00 price target for the company. Morgan Stanley increased their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a report on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Avalyn Pharma in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Avalyn Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.
Read Our Latest Stock Analysis on AVLN
Avalyn Pharma Company Profile
Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.
Read More
- Five stocks we like better than Avalyn Pharma
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
